1. Home
  2. USNA vs LCTX Comparison

USNA vs LCTX Comparison

Compare USNA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo USANA Health Sciences Inc.

USNA

USANA Health Sciences Inc.

N/A

Current Price

$17.40

Market Cap

382.1M

Sector

Health Care

ML Signal

N/A

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

N/A

Current Price

$1.62

Market Cap

407.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USNA
LCTX
Founded
1992
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
382.1M
407.7M
IPO Year
1996
1996

Fundamental Metrics

Financial Performance
Metric
USNA
LCTX
Price
$17.40
$1.62
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.00
AVG Volume (30 Days)
129.1K
1.0M
Earning Date
01-01-0001
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.67
N/A
Revenue
$1,060,902,000.00
$14,556,000.00
Revenue This Year
$3.89
$55.75
Revenue Next Year
$6.22
$2.96
P/E Ratio
$26.28
N/A
Revenue Growth
N/A
53.24
52 Week Low
$16.80
$0.37
52 Week High
$38.32
$2.09

Technical Indicators

Market Signals
Indicator
USNA
LCTX
Relative Strength Index (RSI) 28.88 39.21
Support Level N/A $1.55
Resistance Level $21.35 $1.84
Average True Range (ATR) 0.72 0.10
MACD -0.36 -0.03
Stochastic Oscillator 7.42 4.50

Price Performance

Historical Comparison
USNA
LCTX

About USNA USANA Health Sciences Inc.

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: